Screener
Relmada Therapeutics, Inc. RLMD Other operating expenses
Other operating expenses at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001213900-26-055059
| Line item | Three months ended / March 31, 2026 | Three months ended / March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | $8,087,845 | $11,951,023 |
| General and administrative | 11,373,909 | 6,267,412 |
| Total operating expenses | 19,461,754 | 18,218,435 |
| Loss from operations | (19,461,754) | (18,218,435) |
| Other income: | ||
| Interest/investment income, net | 959,762 | 440,287 |
| Realized (loss)/gain on short-term investments | (9,867) | 62,952 |
Item 1. Unaudited Condensed Consolidated Financial Statements
FAQ
- What is Relmada Therapeutics, Inc.'s other operating expenses?
- Relmada Therapeutics, Inc. (RLMD) reported other operating expenses of $19.46M in Q1 2026.
- How has Relmada Therapeutics, Inc.'s other operating expenses changed year-over-year?
- Relmada Therapeutics, Inc.'s other operating expenses increased by 6.8% year-over-year, from $18.22M to $19.46M.
- What is the long-term trend for Relmada Therapeutics, Inc.'s other operating expenses?
- Over 4 years (2021 to 2025), Relmada Therapeutics, Inc.'s other operating expenses has grown at a -17.2% compound annual growth rate (CAGR), from $125.7M to $59.1M.
- What does other operating expenses mean?
- Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.
Ask your AI about Relmada Therapeutics, Inc.'s other operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude